Abstract: A process for preparing and isolating pharmaceutical active ingredient particles having a particle size of between about 0.1 and 30 microns, wherein a slurry comprising the active ingredient and one or more pharmaceutically acceptable excipients is fed into a thin film evaporator under suitable conditions for less than 10 minutes sufficient to generate solid matrix particles comprising active ingredient and one or more excipients, wherein the particles have less than 5% residual solvent.

Abstract: In one aspect, methods of HMF production are described herein. A method of HMF production, in some embodiments, comprises providing a saccharide feedstock including glucose and bringing the saccharide feedstock into contact with a solid state catalytic structure at a temperature sufficient to effectuate dehydration of the glucose to provide HMF. The solid state catalytic structure comprises a substrate having one or more surfaces functionalized with saccharide solubilization functionalities and acid functionalities, wherein the saccharide solubilization functionalities comprise one or more imidazolium salts pendant along chains of a first polymeric species attached to the substrate surface.

Abstract: The present invention provides a process for the production of 1,4-BDO and THF from furan, said process comprising: (i) contacting furan with hydrogen and water in a reactor in the presence of a catalytic composition, wherein the furan and water are contacted in the presence of a solvent, said solvent being selected from one or more of THF, 1,4-BDO and NBA, and converting at least a portion of said furan to 1,4-BDO and THF; (ii) producing a reactor product stream comprising gases, water, THF, 1,4-BDO and furan; (iii) separating gases from the reactor product stream; (iv) then separating at least a portion of each of the THF and 1,4-BDO from said reactor product stream; and (v) recycling the remainder of the reactor product stream, comprising water, optionally furan, and at least one of THF, 1,4-BDO and NBA, to the reactor.

Abstract: The invention describes processes to prepare levulinic acid, formic acid and/or hydroxymethyl furfural from various biomass materials.

Abstract: Biomass feedstocks (e.g., plant biomass, animal biomass, and municipal waste biomass) are processed to produce useful products, such as fuels. For example, systems are described that can convert feedstock materials to a sugar solution, especially, xylose, which can then be chemically converted to furfural and furfural-derived products.

Abstract: The present invention provides a process for the preparation of 1,4-butanediol and tetrahydrofuran said process comprising contacting furan with hydrogen and water in the presence of a supported catalytic composition comprising at least one first metal selected from those in groups 8 to 10 of the periodic table and a further metal selected from manganese, molybdenum, niobium and tungsten.

Abstract: The present invention provides a process for the production of THF and 1,4-BDO from furan in the presence of a catalytic composition, wherein the catalytic composition contains at least one metal selected from the group consisting of Fe, Ru, Os, Co, Rh, Jr, Ni, Pd, Pt and, optionally, contains one or more additional metal on a solid support, and wherein said process comprises the steps of: i) contacting furan with hydrogen and water in a reactor in the presence of said catalytic composition for a time; ii) stopping the flow of furan and the flow of water to the reactor and removing furan and water from the reactor; iii) subjecting the catalytic composition to a gas stream comprising hydrogen at a temperature of from 200 to 600° C. in the absence of the furan and water; iv) re-starting the flow of furan and the flow of water to the reactor.

Abstract: The present invention provides a process for the treatment of a liquid first furan stream comprising furan and carbon monoxide, said process comprising the steps of: i) contacting said first furan stream with a CO-lean first gaseous stream; and ii) stripping at least a portion of the carbon monoxide in the first furan stream into the first gaseous stream to produce a second furan stream comprising less carbon monoxide than the first furan stream and a CO-enriched second gaseous stream.

Abstract: The present invention provides a process for the production of furan, said process comprising the steps of: i) contacting furfural with a decarbonylation catalyst in a decarbonylation reactor to produce a gaseous decarbonylation reaction product stream comprising furan and carbon monoxide; ii) contacting said gaseous decarbonylation reaction product stream with a solvent stream comprising furfural; iii) absorbing at least a portion of the furan present in the gaseous decarbonylation reaction product stream into the solvent stream to provide a furan-containing solvent stream and a gaseous stream comprising carbon monoxide; iv) separating the furan from the furan containing solvent stream by distillation to provide a first furan stream; and v) using at least a portion of the remaining solvent stream comprising furfural as at least a portion of the furfural provided to the decarbonylation reactor.

Abstract: A method for producing a linear hydrocarbon, including reacting a linear aliphatic aldehyde in the presence of at least one metal ion selected from the group consisting of a vanadium ion, a manganese ion, an iron ion, a cobalt ion, an iridium ion, a copper ion, and a thallium ion.

Abstract: The invention is directed to methods of inducing apoptosis, arresting cell cycle, or inhibiting cellular proliferation, or any combination thereof, in a tumor cell, by administration of an effective amount of an N-acyl homoserine lactone analog (AHL), optionally in conjunction with a tumor modulating agent such tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) to the patient. Novel bioactive analogs of an N-acyl homoserine lactone are also provided.

Abstract: The use of one or more compounds of the formula (I) in which R is a straight-chain or branched saturated alkyl group having 5 to 11 carbon atoms or a straight-chain or branched mono- or polyunsaturated alkenyl group having 5 to 11 carbon atoms as antimicrobially active compound is described. The use is preferably in cosmetic, dermatological or pharmaceutical compositions, in crop protection formulations, in washing or cleaning compositions or in paints or coatings.

Abstract: An efficient, hydrogen gas-free, high yielding, moderate temperature and safe-to-handle process for producing furan and its derivatives from furfural, which comprises contacting furfural and water-isopropanol mixture with a supported Pd or Pt catalyst at a temperature in the range of 200-250° C., is reported.

Abstract: The invention is directed to methods of inducing apoptosis, arresting cell cycle, or inhibiting cellular proliferation, or any combination thereof, in a tumor cell, by administration of an effective amount of an N-acyl homoserine lactone analog (AHL), optionally in conjunction with a tumor modulating agent such tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) to the patient. Novel bioactive analogs of an N-acyl homoserine lactone are also provided.

Abstract: Disclosed is an oxidation process to produce a crude carboxylic acid product carboxylic acid product. The process comprises oxidizing a feed stream comprising at least one oxidizable compound to generate a crude carboxylic acid slurry comprising furan-2,5-dicarboxylic acid (FDCA) and compositions thereof. Also disclosed is a process to produce a dry purified carboxylic acid product by utilizing various purification methods on the crude carboxylic acid.

Abstract: The invention describes processes to prepare levulinic acid, formic acid and/or hydroxymethyl furfural from various biomass materials.

Abstract: A method and integrated reactor system are provided for producing one or more organic acids, organic acid degradation compounds, and combinations thereof, from various types of biomass, including sludge from a pulp and paper mill.

Abstract: Multiple catalytic processing stations enable a method for producing volatile gas streams from biomass decomposition at discrete increasing temperatures. These catalytic processing stations can be programmed to maximize conversion of biomass to useful renewable fuel components based on input feedstock and desired outputs.

Abstract: The present invention refers to a process for production of a mixture including 2,4-furandicarboxylic acid (2,4-FDCA) and 2,5 furandicarboxylic acid (2,5-FDCA) through the disproportionation route, using as base compounds oxidation products of furfural. This invention also relates to a process for production of 2,4-FDCA as a result of a disproportionation route and the use of 2,4-FDCA as a monomer or comonomer to synthesize esters or any compounds which can generate macromolecules, such as polyesters.

Abstract: The present invention relates to a method for the treatment or prophylaxis of a disease associated with hyperproliferative cellular division, comprising administering to a subject in need thereof a therapeutically effective dosage of the pharmaceutical composition comprising xanthanodien, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Abstract: A process which isolates tetrahydrofuran from a stream of tetrahydrofuran, alkanol and high boilers, by: (a) separating off a first stream of tetrahydrofuran and alkanol as azeotrope in a first distillation stage; (b) feeding part of the first stream into a reactor for esterifying maleic anhydride, giving a second stream of tetrahydrofuran and monoalkyl maleate; (c) separating the second stream into a third stream of monoalkyl maleate and a fourth stream of tetrahydrofuran in a second distillation stage; (d) feeding the fourth stream of tetrahydrofuran from the second distillation stage and the part of the first stream from (a) which is not fed to the reactor into a third distillation stage to obtain a product stream of tetrahydrofuran and a sixth stream of tetrahydrofuran and alkanol; (e) recirculating the sixth stream from the third distillation stage into the first distillation stage or the reactor in (b).

Abstract: The present invention provides catalysts, methods, and reactor systems for converting oxygenated hydrocarbons to oxygenated compounds. The invention includes methods for producing cyclic ethers, monooxygenates, dioxygenates, ketones, aldehydes, carboxylic acids, and alcohols from oxygenated hydrocarbons, such as carbohydrates, sugars, sugar alcohols, sugar degradation products, and the like, using catalysts containing palladium, molybdenum, tin, and tungsten. The oxygenated compounds produced are useful in the production of liquid fuels, chemicals, and other products.

Abstract: The invention provides a liquid crystal compound that has an excellent compatibility with other liquid crystal compounds and also has at least one of characteristics such as a high stability to heat, light or the like, a suitable refractive index anisotropy (?n), a low threshold voltage and a suitable dielectric anisotropy (??). A compound represented by formula (1) For example, R1 is alkyl having 1 to 10 carbons, R2 is halogen or alkenyl having 2 to 10 carbons; the ring A1, the ring A2 and the ring A3 are 1,4-cyclohexylene or 1,4-phenylene; Z1, Z2 and Z3 are a single bond or alkylene having 1 to 4 carbons; G is —CH2— or —O—; and m is 1, and n and p is 0 or 1.

Abstract: A process for purifying a crude furan 2,5-dicarboxylic acid composition (cFDCA) by hydrogenation of a FDCA composition dissolved in a hydrogenation solvent such as water, and hydrogenating under mild conditions, such as at a temperature within a range of 130° C. to 225° C. by contacting the solvated FDCA composition with hydrogen in the presence of a hydrogenation catalyst under a hydrogen partial pressure within a range of 10 psi to 900 psi. A product FDCA composition is produced having a low amount of tetrahydrofuran dicarboxylic acid, a low b*, and a low amount of 5-formyl furan-2-carboxylic acid (FFCA).

Abstract: The invention relates to a method for the extraction of all unsaponifiable fraction contained in a vegetable oil, an oil originating from a micro-organism or a vegetable butter or in a co-product from the vegetable oil refining industry, such as deodorization discharge. The method includes at least: A) a step comprising the transformation of the aforementioned oils, butter or co-product from the vegetable oil refining industry or oils originating from micro-organisms into a hydro-alcoholic solution by means of, in particular, a step selected from saponification and esterification steps; B) a step comprising the extraction of the hydro-alcoholic solution in which the fatty fraction is separated from the unsaponifiable fraction by means of liquid/liquid extraction; and C) an optional step comprising the purification of the unsaponifiable fraction, selected from the group containing crystallization and liquid/liquid extraction steps.

Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: Disclosed herein are substituted quinoxaline carboxylic acids of Formula (I): and compositions thereof, which may be useful as inhibitors of PAS Kinase (PASK) activity in a human or animal for the treatment of diseases such as diabetes mellitus.

Abstract: Substituted imidazo[1,5-a]quinoxalin-4-one compounds of formula (I) described herein exhibit PDE9-inhibitory action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like.

Abstract: Described herein are single step methods of making various classes of alkylamine derivatives of furan and tetrahydrofuran by simultaneous contact of a sugar with H2, an acid catalyst and hydrogenation catalyst in the presence of an alkylamide solvent. The hydrogenation catalyst is a heterogeneous catalyst comprising a metal selected from the group consisting of Pt, Pd, and nickel. The acid catalysts may be homogeneous mineral acid or a heterogeneous acid catalyst on substrate. In a preferred practice the two catalysts are provided on a common heterogeneous bifunctional support. Using similar combinations of acid and hydrogenation catalysts, there is also described single step methods for making furandimethanol by simultaneously contacting a hexose with the two separate catalysts in the presence of H2 in an aprotic solvent, such as dimethylformamide.

Abstract: The subject of the present invention is a novel process for the preparation of N-[2-n-butyl-3-{4-[(3-dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide of formula I: and the new intermediates of the preparation process.

Abstract: Disclosed herein are processes comprising contacting isosorbide with hydrogen in the presence of a first hydrogenation catalyst to form a first product mixture comprising tetrahydrofuran-2,5-dimethanol. The processes can further comprise heating the first product mixture in the presence of hydrogen and a second hydrogenation catalyst to form a second product mixture comprising 1,6-hexanediol. The first and second hydrogenation catalysts can be the same or different.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.

Abstract: The present invention discloses novel naphtho[2,3-b]furan-4,9-diones and naphtho[2,3-b]thiophene-4,9-diones and methods of making and using the same. The present invention also discloses pharmaceutical compositions comprising novel naphtho[2,3-b]furan-4,9-dione or naphtho[2,3-b]thiophene-4,9-diones for the treatment of various indications including proliferative diseases.

Abstract: The present invention concerns compounds of general formula (I): Method of preparation and uses thereof.

Abstract: A topical liquid formulation is provided which contains a combination of three active ingredients for treating fleas and ticks in domestic animals. Total concentration of the active hydrophobic and hydrophilic ingredients can exceed 60 weight percent. In contrast to commonly available flea treatments, the new insecticidal composition is safe and effective for both felines and canines and a single topical application can be effective for at least several weeks.

Abstract: The present invention refers to compounds of formula (I): as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or chemoprevention of cancer, aging related diseases or processes, diabetes and neurodegenerative diseases.

Abstract: The present invention relates to pyrrolopyrazines compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.

Abstract: Triphenylene containing benzo-fused thiophene compounds are provided. Additionally, triphenylene containing benzo-fused furan compounds are provided. The compounds may be useful in organic light emitting devices, particularly as hosts in the emissive layer of such devices, or as materials for enhancement layers in such devices, or both.

Abstract: Disclosed are novel cross-linkable end-cappers for oligo- and polyimides. End-capped oligo- and polyimides comprising such an end-capper may be cured at a lower temperature compared to oligo- and polyimides end-capped with PEPA.

Abstract: The present invention provides a method for depolymerization of a mixture comprising oligomeric cyclic ethers resulting from copolymerization of at least one tetrahydrofuran and at least one other cyclic ether to recover tetrahydrofuran monomer.

Abstract: Nitromethylene analogues of imidacloprid and divalent and oxabridged heterocyclic neonicotinoid compounds constructed by dialdehydes, preparation methods and uses thereof are disclosed. Compounds represented by formula (A) or (B), their optical isomers or agrochemically acceptable salts are provided. Agrochemical compositions comprising the said compounds, their optical isomers or agrochemically acceptable salts, the uses of the said agrochemical compositions and the preparation methods of the said compounds, their optical isomers or agrochemically acceptable salts are also disclosed. The compounds and their derivatives have high insecticidal activities to several farming and forestry pests including homoptera and lepidoptera pests, such as aphis, fulgorid, whitefly, leafhopper, common thrips, cotton bollworm, cabbage caterpillar, cabbage moth, cotton leafworm and armyworm.

Abstract: Compounds corresponding to the general formula (I) wherein R2 represents a group C1-10-alkyl, C3-10-cycloalkyl, C3-7-cycloalkyl-C1-6-alkyl, C1-6-alkyl-C3-7-cycloalkyl, C3-7-cycloalkyl-C3-7-cycloalkyl, C1-6-alkylthio-C-1-10-alkyl, C1-6-alkoxy-C1-10-alkyl, hydroxy-C1-10-alkyl, hydroxy-C1-6-alkyl-C3-7-cycloalkyl-C1-6-alkyl, hydroxy-C3-10-cycloalkyl, C1-10-fluoroalkyl or C3-10-fluorocycloalkyl; an optionally substituted heterocyclic group; a group C1-10-alkyl substituted with an optionally substituted heterocyclic group; X6 represents a group chosen from hydrogen, fluorine, chlorine and bromine atoms or a group C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-6-alkyl, C1-6-fluoroalkyl or cyano; and R7 represents an aryl group such as phenyl or naphthyl, optionally substituted with one or more substituents, in the form of the base or of an acid-addition salt, and the therapeutic use thereof.

Abstract: The invention provides new pyridopyrazine compounds according to formula (I) which are highly selective as Ras-Raf-Mek-Erk signal transduction pathway inhibitors and in particular are highly selective Erk inhibitors.

Abstract: The present invention relates to pyridazinone derivatives of general formula I, wherein the groups A, G and R1 are as defined in the application, the tautomers thereof, stereoisomers thereof, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

Abstract: Described is a process to produce hydroxymethyl furfural (HMF) from biomass-derived sugars. The process includes the steps of reacting a C5 and/or C6 sugar-containing reactant derived from biomass in a monophasic or biphasic reaction solution comprising water and a co-solvent. The co-solvent can be beta-, gamma-, and/or delta-lactones derived from biomass, tetrahydrofuran (THF) derived from biomass, and/or methyltetrahydrofuran (MTHF) derived from biomass. The reaction takes place in the presence of an acid catalyst and a dehydration catalyst for a time and under conditions such that at least a portion of glucose or fructose present in the reactant is converted to HMF.

Abstract: The present invention is aimed to provide a 1,4-butanediol-containing composition having high thermal stability as compared with conventional 1,4BG, and the present invention is concerned with a 1,4-butanediol-containing composition having a concentration of 1,4-butanediol of 99.00% by weight or more and not more than 99.99% by weight and containing an amide compound in a concentration, as converted into a nitrogen atom, of from 1.0 to 50 ppm by weight.

Abstract: The present invention relates to a pharmaceutical composition comprising specific compounds which may be obtained from Leontopodium alpinum Cass. (Edelweiss). A preferred compound is leoligin (=(2S,3R,4R)-4-(3,4-dimethoxybenzyl) -2-(3,4-dimethoxyphenyl)tetrahydrofuran-3-yl]methyl(2Z)-2-methylbut-2-enoat]). Corresponding means and methods in respect of medical uses of the compounds are described. The present invention also provides a medical device comprising, containing or having been contacted with the compound. The compounds provided herein may particularly be used in the treatment of hyperplastic diseases, in particular intimal hyperplasia, e.g. stenosis, restenosis, atherosclerosis and the like. Also envisaged herein is the use of these compounds in the treatment of proliferative diseases, such as leukemia, prostate cancer and lung cancer.

Abstract: A process to produce a dry purified furan-2,5-dicarboxylic acid (FDCA) is described. After oxidation of 5-(hydroxymethyl)furfural (5-HMF), a crude FDCA stream is produced that is fed to a crystallization zone followed by a solid-liquid displacement zone to form a low impurity slurry stream. The solids in the low impurity slurry stream are dissolved in a dissolution zone to produce a hydrogenation feed that is hydrogenated in a hydrogenation reactor to generate a hydrogenated FDCA composition. The hydrogenated FDCA composition is routed to a crystallization zone to form a crystallized produce stream that is separated from liquid in a solid-liquid separation zone to generate a purified wet cake stream containing FDCA that can be dried in a drying zone to generate a dry purified FDCA product stream.

Abstract: A novel class of diyne compounds and diyne salts provided herein are effective and potent Ole1 protein inhibitors, useful for treating fungal pathogens. Compounds, fungicides and methods are provided as novel, potent and broad spectrum anti-fungal agents for treatment against a wide variety of fungal pathogens in humans and animals, and in the agricultural setting.